Genmab Outlines Development Plans For HuMax-CD4 After Regaining Rights From Merck Serono
This article was originally published in The Pink Sheet Daily
Executive Summary
Merck returns rights to the investigational T-cell lymphoma candidate for strategic reasons prior to seeing Phase III data.
You may also be interested in...
Genmab Reins In, Looks To Partners
Once hailed by some as a potential "European Genentech," antibody player Genmab AS is emerging far humbler from the other side of a radical strategic and financial overhaul. Hit by a series of development delays, cost overruns and some poor decision-making, the company has reined in its one-time ambition to become a fully integrated, commercial outfit.
Genmab Reins In, Looks To Partners
Once hailed by some as a potential "European Genentech," antibody player Genmab AS is emerging far humbler from the other side of a radical strategic and financial overhaul. Hit by a series of development delays, cost overruns and some poor decision-making, the company has reined in its one-time ambition to become a fully integrated, commercial outfit.
Genmab To Initiate HuMax-Inflam Glioblastoma Trial In 2008
Other potential indications for the interleukin-8 antibody include chronic obstructive pulmonary disease.